The Society for Immunotherapy of Cancer's (SITC) 36 Annual Meeting
The 36th Annual Meeting of the Society for Immunotherapy in Cancer – SITC 2021 – will take place 10 – 14 November 2021 in Washington, DC, USA.
Our Oncology team will join virtually and explore if our biomarker for neutrophil activity can be used for immunotherapy in different solid tumor types.
Christina Jensen and Nicholas Willumsen will present two posters at the upcoming SITC Annual Meeting.
In one of them, we show that high levels of a serum calprotectin assay (CPa9-HNE), as a measure of neutrophil activity, are associated with poor response to anti-PD-1 therapy in metastatic melanoma patients.
Furthermore, we observed elevated CPa9-HNE levels in patients with different solid tumor types. These findings may indicate that CPa9-HNE may be used as a biomarker for anti-PD-1 therapy across different solid tumor types.
